"Institución de referencia en la región y en el país, líder en las prácticas asistenciales que brinda (generando salud y bienestar con sentido humano), referencia local, nacional e internacional en proyectos de investigación biomédica."

During the past decade, Instituto de Cardiología de Corrientes conducted 19 clinical trials. In the 10-year time frame, 19 clinical trials started and 14 clinical trials were completed, i.e. on average, 73.7% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 8 clinical trials were completed. i.e. 88.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Instituto de Cardiología de Corrientes" #1 sponsor was "Boehringer Ingelheim" with 6 trials, followed by "Actelion" with 4 trials sponsored, "Gilead Sciences" with 4 trials sponsored, "Bayer" with 3 trials sponsored and "Pfizer" with 3 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Instituto de Cardiología de Corrientes" #1 collaborator was "Eli Lilly and Company" with 4 trials as a collaborator, "Brigham and Women's Hospital" with 1 trials as a collaborator, "Canadian VIGOUR Centre" with 1 trials as a collaborator, "Drugs for Neglected Diseases initiative" with 1 trials as a collaborator and "Duke Clinical Research Institute" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Instituto de Cardiología de Corrientes" are "Pulmonary Arterial Hypertension" (8 trials), "Hypertension" (5 trials), "Pulmonary Hypertension" (5 trials), "Atrial Fibrillation" (3 trials) and "Cardiovascular Diseases" (3 trials). Many other conditions were trialed in "Instituto de Cardiología de Corrientes" in a lesser frequency.

Most popular intervention types in "Instituto de Cardiología de Corrientes" are "Drug" (31 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (15 trials), "Empagliflozin" (3 trials), "Ralinepag" (3 trials), "Darusentan" (2 trials) and "Guanfacine" (2 trials). Other intervention names were less common.

The vast majority of trials in "Instituto de Cardiología de Corrientes" are 32 trials for "All" genders.

Currently, there are NaN active trials in "Instituto de Cardiología de Corrientes". undefined are not yet recruiting, 4 are recruiting, 5 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 15 completed trials in Instituto de Cardiología de Corrientes, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Instituto de Cardiología de Corrientes, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 28 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".